Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 7
Submit an article Journal homepage
736
Views
0
CrossRef citations to date
0
Altmetric
Review

Evaluation of 5-Fluorouracil Pharmacokinetic Models and Therapeutic Drug Monitoring in Cancer Patients

André BP van Kuilenburg1 Academic Medical Center, University of Amsterdam, Emma Children‘s Hospital & Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, F0-220, Meibergdreef 9, 1105AZAmsterdam, The NetherlandsCorrespondence[email protected]
&
Jan Gerard Maring2 Diaconessen Hospital Meppel & Bethesda Hospital Hoogeveen, Department of Pharmacy, Meppel, The Netherlands
Pages 799-811 | Published online: 08 May 2013

References

  • Touw DJ , NeefC, ThomsonAH, VinksAA. Cost–effectiveness of therapeutic drug monitoring: a systematic review. Ther. Drug Monit.27(1) , 10–17 (2005).
  • Mitchell PB . Therapeutic drug monitoring of psychotropic medications. Br. J. Clin. Pharmacol.52(Suppl. 1) , S45–S54 (2001).
  • Hiemke C , BaumannP, BergemannN et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44(6) , 195–235 (2011).
  • Bartelink IH , BrediusRG, VerversTT et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 14(1) , 88–98 (2008).
  • Malar R , SjooF, RentschK, HassanM, GungorT. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr. Transplant.15(6) , 580–588 (2011).
  • Evans WE , RellingMV, RodmanJH, CromWR, BoyettJM, PuiCH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med.338(8) , 499–505 (1998).
  • Saleem M , DimeskiG, KirkpatrickCM, TaylorPJ, MartinJH. Target concentration intervention in oncology: where are we at? Ther. Drug Monit.34(3) , 257–265 (2012).
  • Gamelin E , Boisdron-CelleM, Guérin-MeyerV et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J. Clin. Oncol. 17(4) , 1105–1110 (1999).
  • Capitain O , AsevoaiaA, Boisdron-CelleM, PoirierAL, MorelA, GamelinE. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a Phase II, proof-of-concept study. Clin. Colorectal Cancer11(4) , 263–267 (2012).
  • Kaldate RR , HaregewoinA, GrierCE, HamiltonSA, McLeodHL. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist17(3) , 296–302 (2012).
  • Boisdron-Celle M . Pharmacokinetic adaptation of 5-fluorouracil: where are we and where are we going? Pharmacogenomics13(13) , 1437–1439 (2012).
  • Meyerhardt JA , MayerRJ. Systemic therapy for colorectal cancer. N. Engl. J. Med.352(5) , 476–487 (2005).
  • Twelves C , WongA, NowackiMP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 352(26) , 2696–2704 (2005).
  • Andre T , BoniC, NavarroM et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27(19) , 3109–3116 (2009).
  • Tournigand C , AndreT, BonnetainF et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J. Clin. Oncol. 30(27) , 3353–3360 (2012).
  • van Loon K , VenookAP. Adjuvant treatment of colon cancer: what is next? Curr. Opin. Oncol.23(4) , 403–409 (2011).
  • Benson AB 3rd, Bekaii-Saab T, Chan E et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN guidelines. J. Natl Compr. Canc. Netw.11(2) , 141–152 (2013).
  • Gusella M , CrepaldiG, BarileC et al. Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. Ann. Oncol. 17(11) , 1656–1660 (2006).
  • Milano GA , EtienneMC, RenéeN et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J. Clin. Oncol. 12(6) , 1291–1295 (1994).
  • Gamelin E , Boisdron-CelleM, DelvaR et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J. Clin. Oncol. 16(4) , 1470–1478 (1998).
  • Milano GA , EtienneMC, Cassuto-ViguierE et al. Influence of sex and age on fluorouracil clearance. J. Clin. Oncol. 10(7) , 1171–1175 (1992).
  • Etienne MC , ChatelutE, PivotX et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur. J. Cancer 34(1) , 92–97 (1998).
  • Saif MW , ChomaA, SalamoneSJ, ChuE. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J. Natl Cancer Inst.101(22) , 1543–1552 (2009).
  • van Kuilenburg ABP , HauslerP, SchalhornA et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin. Pharmacokinet. 51(3) , 163–174 (2012).
  • Mattison LK , SoongR, DiasioRB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics3(4) , 485–492 (2002).
  • van Kuilenburg ABP . Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer40(7) , 939–950 (2004).
  • van Kuilenburg ABP , HaasjesJ, RichelDJ et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 6(12) , 4705–4712 (2000).
  • Milano GA , EtienneMC, PierrefiteV, Barberi-HeyobM, Deporte-FetyR, RenéeN. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer79(3–4) , 627–630 (1999).
  • Ciccolini J , MercierC, EvrardA et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther. Drug Monit. 28(5) , 678–685 (2006).
  • Di Paolo A , DanesiR, FalconeA et al. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann. Oncol. 12(9) , 1301–1306 (2001).
  • Gamelin E , Boisdron-CelleM. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer – status of the art. Crit Rev. Oncol. Hematol.30(1) , 71–79 (1999).
  • Maring JG , van Kuilenburg ABP, Haasjes J et al. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br. J. Cancer86(7) , 1028–1033 (2002).
  • Gamelin E , DelvaR, JacobJ et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J. Clin. Oncol. 26(13) , 2099–2105 (2008).
  • Terret C , ErdociainE, GuimbaudR et al. Dose and time dependencies of 5-fluorouracil pharmacokinetics. Clin. Pharmacol. Ther. 68(3) , 270–279 (2000).
  • Collins JM , DedrickRL, KingFG, SpeyerJL, MyersCE. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin. Pharmacol. Ther.28(2) , 235–246 (1980).
  • Collins JM . Pharmacokinetics of 5-fluorouracil infusions in the rat: comparison with man and other species. Cancer Chemother. Pharmacol.14(2) , 108–111 (1985).
  • Kissel J , BrixG, BellemannME et al. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res. 57(16) , 3415–3423 (1997).
  • Port RE , SchlemmerHP, BachertP. Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach. Eur. J. Clin. Pharmacol.47(2) , 187–193 (1994).
  • Port RE , BachertP, SemmlerW. Kinetic modeling of in vivo – nuclear magnetic resonance spectroscopy data: 5-fluorouracil in liver and liver tumors. Clin. Pharmacol. Ther.49(5) , 497–505 (1991).
  • Sandstrom M , FreijsA, LarssonR et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J. Clin. Oncol. 14(5) , 1581–1588 (1996).
  • Wagner JG , GyvesJW, StetsonPL et al. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res. 46(3) , 1499–1506 (1986).
  • McDermott BJ , van den Berg HW, Murphy RF. Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients. Cancer Chemother. Pharmacol.9(3) , 173–178 (1982).
  • Chirstophidis N , VajdaFJ, LucasI, DrummerO, MoonWJ, LouisWJ. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin. Pharmacokinet.3(4) , 330–336 (1978).
  • Woloch C , Di Paolo A, Marouani H et al. Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. Curr. Top. Med. Chem.12(15) , 1713–1719 (2012).
  • Larsson PA , CarlssonG, GustavssonB, GrafW, GlimeliusB. Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects. Acta Oncol.35(2) , 207–212 (1996).
  • McLeod HL , SluddenJ, HardySC, LockRE, HawksworthGM, CassidyJ. Autoregulation of 5-fluorouracil metabolism. Eur. J. Cancer34(10) , 1623–1627 (1998).
  • Petit E , MilanoG, LeviF, ThyssA, BailleulF, SchneiderM. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res.48(6) , 1676–1679 (1988).
  • Harris BE , SongR, SoongSJ, DiasioRB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res.50(1) , 197–201 (1990).
  • Metzger G , MassariC, EtienneMC et al. Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. Clin. Pharmacol. Ther. 56(2) , 190–201 (1994).
  • Beumer JH , Boisdron-CelleM, ClarkeW et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther. Drug Monit. 31(6) , 688–694 (2009).
  • Santini J , MilanoG, ThyssA et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br. J. Cancer 59(2) , 287–290 (1989).
  • Fety R , RollandF, Barberi-HeyobM et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin. Cancer Res. 4(9) , 2039–2045 (1998).
  • Ychou M , DuffourJ, KramarA et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a Phase II study using a bimonthly pharmacokinetically intensified LV5-FU2 regimen. Cancer Chemother. Pharmacol. 52(4) , 282–290 (2003).
  • Bocci G , DanesiR, Di Paolo AD et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin. Cancer Res.6(8) , 3032–3037 (2000).
  • Bocci G , BarbaraC, VannozziF et al. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin. Pharmacol. Ther. 80(4) , 384–395 (2006).
  • Di Paolo A , DanesiR, VannozziF et al. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin. Pharmacol. Ther. 72(6) , 627–637 (2002).
  • Heggie GD , SommadossiJP, CrossDS, HusterWJ, DiasioRB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res.47(8) , 2203–2206 (1987).
  • Naguib FN , el Kouni MH. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res.45(11 Pt 1) , 5405–5412 (1985).
  • van Kuilenburg ABP , van Lenthe H, Blom MJ, Mul EP, van Gennip AH. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br. J. Cancer79(3–4) , 620–626 (1999).
  • Stéphan F , EtienneMC, WallaysC, MilanoGA, ClergueF. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities. Am. J. Med.99(6) , 685–688 (1995).
  • Diasio RB , BeaversTL, CarpenterJT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest.81(1) , 47–51 (1988).
  • Codacci-Pisanelli G , PinedoHM, LankelmaJ et al. Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity. J. Chemother. 17(3) , 315–320 (2005).
  • van Kuilenburg ABP , MaringJG, SchalhornA et al. Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene. Nucleosides Nucleotides Nucleic Acids 27 , 692–698 (2008).
  • van Kuilenburg ABP , MeinsmaJR, ZoetekouwL, van Gennip AH. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int. J. Cancer101(3) , 253–258 (2002).
  • Gusella M , FerrazziE, FerrariM, PadriniR. New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus. Ther. Drug Monit.24(3) , 425–431 (2002).
  • Boisdron-Celle M , RemaudG, TraoreS et al. 5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 249 , 271–282 (2007).
  • Mattison LK , EzzeldinH, CarpenterM, ModakA, JohnsonMR, DiasioRB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2–13C-uracil breath test. Clin. Cancer Res.10(8) , 2652–2658 (2004).
  • van Kuilenburg ABP . Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that‘s the question. Cancer Invest.24(2) , 215–217 (2006).
  • Ciccolini J , GrossE, DahanL, LacarelleB, MercierC. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin. Colorectal Cancer9(4) , 224–228 (2010).
  • van Staveren MC , Theeuwes-OonkB, GuchelaarHJ, van Kuilenburg AB, Maring JG. Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother. Pharmacol.68(6) , 1611–1617 (2011).
  • van Kuilenburg ABP , VrekenP, AbelingNG et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum. Genet. 104(1) , 1–9 (1999).
  • Amstutz U , FroehlichTK, LargiaderCR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics12(9) , 1321–1336 (2011).
  • Morel A , Boisdron-CelleM, FeyL et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther. 5(11) , 2895–2904 (2006).
  • Schwab M , ZangerUM, MarxC et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group. J. Clin. Oncol. 26 , 2131–2138 (2008).
  • Deenen MJ , TolJ, BuryloAM et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin. Cancer Res. 17(10) , 3455–3468 (2011).
  • Collie-Duguid ESR , EtienneMC, MilanoGA, McLeodHL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics10(3) , 217–223 (2000).
  • van Kuilenburg ABP , MeijerJ, MulAN et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum. Genet. 128(5) , 529–538 (2010).
  • Gieschke R , BurgerHU, ReignerB, BleschKS, SteimerJL. Population pharmacokinetics and concentration–effect relationships of capecitabine metabolites in colorectal cancer patients. Br. J. Clin. Pharmacol.55(3) , 252–263 (2003).
  • Gieschke R , ReignerB, BleschKS, SteimerJL. Population pharmacokinetic analysis of the major metabolites of capecitabine. J. Pharmacokinet. Pharmacodyn.29(1) , 25–47 (2002).
  • Daniele G , GalloM, PiccirilloMC et al. Pharmacokinetic evaluation of capecitabine in breast cancer. Expert Opin. Drug Metab. Toxicol. 9(2) , 225–235 (2013).
  • Chachad S , PurandareS, MalhotraG, NaiduR. Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer. Cancer Chemother. Pharmacol.71(2) , 287–292 (2013).
  • Coustere C , MentreF, SommadossiJP, DiasioRB, SteimerJL. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemother. Pharmacol.28(2) , 123–129 (1991).
  • Moore MJ , BuntingP, YuanS, ThiessenJJ. Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration. Ther. Drug Monit.15(5) , 394–399 (1993).
  • Bressolle F , JouliaJM, PinguetF et al. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. Cancer Chemother. Pharmacol. 44(4) , 295–302 (1999).
  • Climente-Marti M , Merino-SanjuanM, Almenar-CubellsD, Jimenez-TorresNV. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer. J. Pharm. Sci.92(6) , 1155–1165 (2003).
  • Maring JG , PiersmaH, van Dalen A, Groen HJ, Uges DR, de Vries EG. Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokinetics. Cancer Chemother. Pharmacol.51(2) , 167–173 (2003).
  • Ibrahim T , Di Paolo A, Amatori F et al. Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. J. Clin. Pharmacol.52 , 361–369 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.